Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 26

1.

Recurrent venous thromboembolism after deep vein thrombosis: incidence and risk factors.

Hansson PO, Sörbo J, Eriksson H.

Arch Intern Med. 2000 Mar 27;160(6):769-74.

PMID:
10737276
2.

Predictors of recurrence after deep vein thrombosis and pulmonary embolism: a population-based cohort study.

Heit JA, Mohr DN, Silverstein MD, Petterson TM, O'Fallon WM, Melton LJ 3rd.

Arch Intern Med. 2000 Mar 27;160(6):761-8.

PMID:
10737275
3.

Antithrombotic therapy for venous thromboembolic disease.

Hyers TM, Agnelli G, Hull RD, Weg JG, Morris TA, Samama M, Tapson V.

Chest. 1998 Nov;114(5 Suppl):561S-578S. Review. No abstract available.

PMID:
9822063
4.

Anticoagulation therapy in patients with venous thromboembolic disease.

Whittle J, Johnson P, Localio AR.

J Gen Intern Med. 1998 Jun;13(6):373-8.

5.

Pulmonary embolism.

Goldhaber SZ.

N Engl J Med. 1998 Jul 9;339(2):93-104. Review. No abstract available.

PMID:
9654541
6.
7.

Trends in the incidence of deep vein thrombosis and pulmonary embolism: a 25-year population-based study.

Silverstein MD, Heit JA, Mohr DN, Petterson TM, O'Fallon WM, Melton LJ 3rd.

Arch Intern Med. 1998 Mar 23;158(6):585-93.

PMID:
9521222
8.

Deep vein thrombosis and pulmonary embolism in the general population. 'The Study of Men Born in 1913'.

Hansson PO, Welin L, Tibblin G, Eriksson H.

Arch Intern Med. 1997 Aug 11-25;157(15):1665-70.

PMID:
9250227
9.

Determinants of compliance with anticoagulation: A case-control study.

Arnsten JH, Gelfand JM, Singer DE.

Am J Med. 1997 Jul;103(1):11-7.

PMID:
9236480
10.

Age-specific incidence rates of venous thromboembolism among heterozygous carriers of factor V Leiden mutation.

Ridker PM, Glynn RJ, Miletich JP, Goldhaber SZ, Stampfer MJ, Hennekens CH.

Ann Intern Med. 1997 Apr 1;126(7):528-31.

PMID:
9092318
11.

The duration of oral anticoagulant therapy after a second episode of venous thromboembolism. The Duration of Anticoagulation Trial Study Group.

Schulman S, Granqvist S, Holmström M, Carlsson A, Lindmarker P, Nicol P, Eklund SG, Nordlander S, Lärfars G, Leijd B, Linder O, Loogna E.

N Engl J Med. 1997 Feb 6;336(6):393-8.

12.

Management of venous thromboembolism.

Ginsberg JS.

N Engl J Med. 1996 Dec 12;335(24):1816-28. Review. No abstract available.

PMID:
8943165
13.

Effects of race and income on mortality and use of services among Medicare beneficiaries.

Gornick ME, Eggers PW, Reilly TW, Mentnech RM, Fitterman LK, Kucken LE, Vladeck BC.

N Engl J Med. 1996 Sep 12;335(11):791-9.

14.

Old age and race as determinants of initiation of glaucoma therapy.

Glynn RJ, Gurwitz JH, Bohn RL, Monane M, Choodnovskiy I, Avorn J.

Am J Epidemiol. 1993 Sep 15;138(6):395-406.

PMID:
8213745
15.

The epidemiology of diagnosed pulmonary embolism and deep venous thrombosis in the elderly.

Kniffin WD Jr, Baron JA, Barrett J, Birkmeyer JD, Anderson FA Jr.

Arch Intern Med. 1994 Apr 25;154(8):861-6.

PMID:
8154949
16.

A comparison of six weeks with six months of oral anticoagulant therapy after a first episode of venous thromboembolism. Duration of Anticoagulation Trial Study Group.

Schulman S, Rhedin AS, Lindmarker P, Carlsson A, Lärfars G, Nicol P, Loogna E, Svensson E, Ljungberg B, Walter H.

N Engl J Med. 1995 Jun 22;332(25):1661-5.

17.

A new method of classifying prognostic comorbidity in longitudinal studies: development and validation.

Charlson ME, Pompei P, Ales KL, MacKenzie CR.

J Chronic Dis. 1987;40(5):373-83.

PMID:
3558716
18.

Medicaid data as a resource for epidemiologic studies: strengths and limitations.

Bright RA, Avorn J, Everitt DE.

J Clin Epidemiol. 1989;42(10):937-45.

PMID:
2681546
19.

Use of Medicaid data for pharmacoepidemiology.

Ray WA, Griffin MR.

Am J Epidemiol. 1989 Apr;129(4):837-49.

PMID:
2646920
20.

Antithrombotic therapy for venous thromboembolic disease.

Hyers TM, Hull RD, Weg JG.

Chest. 1989 Feb;95(2 Suppl):37S-51S. Review. No abstract available.

PMID:
2644102

Supplemental Content

Support Center